Core Laboratories N.V.
Core Laboratories N.V. (NYSE: CLB) is a global leader in providing the oil and gas sector with proprietary and patented reservoir description and production enhancement services and solutions. These services and solutions can help its clients to improve reservoir performance and recover more oil and gas from their producing fields. CLB employs roughly 3,700 people and has over 70 offices in 50 countries.
Why should Investors Book Profits?
- Reduction in Topline and Margins: Due to delays in exploration and production projects in offshore and overseas markets, CLB's total revenues fell 3.49% YoY to USD 470.25 million in FY21 (ended December 31, 2021) from USD 487.27 million in FY20. CLB also saw its EBITDA margin drop from 16.5% in FY20 to 13.2% in FY21.
- Leveraged Balance Sheet: The company's debt/equity ratio was 1.21x as of December 31, 2021, compared to the industry median of 0.39x. In addition, its long-term debt-to-total-capital ratio was 54.0%, compared to 18.9% for the same period in the industry. The company's exposure to balance-sheet risk has increased due to this.
- Supplier Concentration Risk: A small number of third-party suppliers and vendors are available in the marketplace for some of the company's product lines. As a result of this concentration in parts of its supply chains, its business and operations could be harmed if its key suppliers' quality or timely delivery of their products were to suffer substantial disruptions.
- Technical Weakness: CLB's prices moved up by ~35.84% from the last recommended entry price and made a high of USD 35.83 on March 08, 2022. Prices reached a crucial resistance level of USD 35.83 but were unable to break this level, indicating the possibility of a downside correction which may lead the prices towards the resistance turned support level of USD 28.55.
- On the weekly chart, RSI (14-period) is reached an overbought zone at 78.86 levels, supporting a downside correction. However, prices are still sustaining above the trend-following indicators 21-period SMA and 50-period SMA and may act as the support levels for the stock.
Valuation Methodology: Price/Earnings Per Share Based Relative Valuation
(Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's FY1 trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.
Stock Recommendation:
CLB's stock price has surged 27.37% in the past week and is currently leaning towards the mid-band of its 52-week range of USD 21.08 to USD 49.87. We have valued the stock using the Price/Earnings-based relative valuation methodology and arrived at a target price of USD 30.00.
Considering the significant rise in the share price in a short span, leveraged balance sheet, the decline in revenues, stress on margins, and other technical indicators, we recommend a "Sell" rating on the stock at the closing price of USD 35.04, up 13.07% as of March 08, 2022.
Three-Year Technical Price Chart (as of March 08, 2022). Source: REFINITIV, Analysis by Kalkine Group
* The reference data in this report has been partly sourced from REFINITIV.
* All forecasted figures and industry information have been taken from REFINITIV.
Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.
Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.
You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.
The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.
Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.
Please also read our Terms & Conditions and Financial Services Guide for further information.
On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.